Leerink Partners Initiates Coverage On MapLight Therapeutics with Outperform Rating, Announces Price Target of $30

MapLight Therapeutics, Inc. +0.82%

MapLight Therapeutics, Inc.

MPLT

18.49

+0.82%

Leerink Partners analyst Marc Goodman initiates coverage on MapLight Therapeutics (NASDAQ: MPLT) with a Outperform rating and announces Price Target of $30.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via